

Corresponding author(s):	Patrick Cramer
Last updated by author(s):	Nov 20, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

<u> </u>			
St	at	121	$1 \cap 9$

FOI	all S	tatistical analyses, commit that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Со	nfirmed
X		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
x		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
×		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
x		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
×		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web cell action an atotistica for his largists contains articles on many of the mainte above

Our web collection on <u>statistics for biologists</u> contains articles on many of the points abov

Software and code

Policy information about availability of computer code

Data collection EPU, pLink 1 (version 2.3.1), pLink 2

Data analysis Warp 1.0.6, RELION 3.0.5, PHENIX 1.16, COOT 0.8.9, PyMOL version 2.2.2, Chimera 1.13, XiNet webserver, xVis webserver, XlinkAnalyzer

version 1.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The electron density reconstructions of the complete SAGA complex, the Tra1 module, the core modules, and the DUB module-nucleosome complex were deposited with the EM Data Base (accession codes EMD-10412, EMD-10413, EMD-10414, EMD-10415, and EMD-10416 respectively) and with the Protein Data Bank (accession codes 6T9I, 6T9I, 6T9I, 6T9K, and 6T9L, respectively).

Field-specific reporting

Life sciences study design

Commonly misidentified lines

(See <u>ICLAC</u> register)

All studies must dis	close on these	points even when the disclosure is negative.		
Sample size	No statistical methods were used to predetermine sample size. All biochemical experiments were replicated two or more times. The crosslinking mass spectrometry measurement was replicated twice as a standard procedure for the method.			
Data exclusions	No data were e	No data were excluded from the analyses.		
Replication	All attempts at r	eplication were successful by comparing the result of each replicate.		
Randomization	Samples were n	ot allocated to groups.		
Blinding	Investigators were not blinded during data acquisition and analysis because it is not a common procedure for the methods employed.			
Reportin	g for sp	ecific materials, systems and methods		
		bout some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, our study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	perimental sy	vstems Methods		
n/a Involved in the study		n/a Involved in the study		
X Antibodies		ChIP-seq		
Eukaryotic	cell lines	Flow cytometry		
× Palaeontolo	0,	MRI-based neuroimaging		
	d other organism			
Human research participants				
x Clinical dat	a			
Eukaryotic c	ell lines			
Policy information a	about <u>cell lines</u>			
Cell line source(s))	Saccharomyces cerevisiae strain CB010 (MATa pep4::HIS3, prb1::LEU2, prc1::HISG, can1, ade2, trp1, ura3, his3, leu2-3,112)		
Authentication None of the cell lin		None of the cell lines used were authenticated.		
Mycoplasma contamination Cell lines were not		Cell lines were not tested for mycoplasma contamination.		

No commonly misidentified cell lines were used.